Brief: Genexine Receives Fast Track Designation From Korean Health Authority For Vaccine For Advanced Cervical Cancer
20/01/2023 20:54
Jan 20 (Reuters) - Genexine Inc 095700.KQ :
* GENEXINE RECEIVES FAST TRACK DESIGNATION FROM KOREAN
HEALTH
AUTHORITY (MFDS) FOR ITS PROMISING DNA VACCINE FOR ADVANCED
CERVICAL CANCER
Source text for Eikon: ID:nBw1qC1vCa
Further company coverage: 095700.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genexine
See all newsBrief: Genexine Announces Merger With EPD Biotherapeutics
Brief: Genexine To Invest 29 Billion Won As Part Of Consortium In Building New Research And Development Centre In Seoul, South Koreａ
Brief: Genexine To Divest 19 Billion Won Worth Of Shares In Ajinomoto Genexine Co
Brief: Genexine Receives Fast Track Designation From Korean Health Authority For Vaccine For Advanced Cervical Cancer
Indonesia in talks with WHO to become global vaccine hub: minister